Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Purchased by JPMorgan Chase & Co.

JPMorgan Chase & Co. lifted its position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 75.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 859,710 shares of the company's stock after buying an additional 370,511 shares during the period. JPMorgan Chase & Co. owned approximately 1.21% of Zentalis Pharmaceuticals worth $2,605,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Prudential Financial Inc. purchased a new position in shares of Zentalis Pharmaceuticals in the 4th quarter worth approximately $39,000. Ieq Capital LLC purchased a new position in shares of Zentalis Pharmaceuticals in the 4th quarter worth approximately $46,000. Meriwether Wealth & Planning LLC purchased a new position in shares of Zentalis Pharmaceuticals in the 4th quarter worth approximately $66,000. Raymond James Financial Inc. purchased a new stake in Zentalis Pharmaceuticals during the 4th quarter worth approximately $68,000. Finally, Savant Capital LLC purchased a new stake in Zentalis Pharmaceuticals during the 4th quarter worth approximately $72,000.

Insider Transactions at Zentalis Pharmaceuticals

In other Zentalis Pharmaceuticals news, Director Jan Skvarka bought 60,000 shares of the company's stock in a transaction dated Friday, January 31st. The stock was acquired at an average price of $1.72 per share, with a total value of $103,200.00. Following the completion of the acquisition, the director now directly owns 149,551 shares of the company's stock, valued at $257,227.72. This represents a 67.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Ingmar Bruns bought 20,000 shares of the company's stock in a transaction dated Thursday, February 6th. The shares were acquired at an average cost of $2.28 per share, with a total value of $45,600.00. Following the acquisition, the insider now directly owns 36,629 shares of the company's stock, valued at approximately $83,514.12. This represents a 120.27 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 3.60% of the company's stock.

Zentalis Pharmaceuticals Trading Down 0.7 %

NASDAQ:ZNTL traded down $0.01 during trading hours on Monday, reaching $1.42. 542,549 shares of the company were exchanged, compared to its average volume of 1,547,366. The stock's 50-day moving average is $1.64 and its 200-day moving average is $2.49. The firm has a market cap of $101.97 million, a PE ratio of -0.57 and a beta of 1.80. Zentalis Pharmaceuticals, Inc. has a twelve month low of $1.01 and a twelve month high of $13.24.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last posted its quarterly earnings data on Wednesday, March 26th. The company reported ($0.66) earnings per share for the quarter, topping analysts' consensus estimates of ($0.75) by $0.09. The company had revenue of $26.90 million for the quarter. As a group, research analysts anticipate that Zentalis Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Wall Street Analyst Weigh In

ZNTL has been the topic of several research analyst reports. Wells Fargo & Company dropped their target price on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an "equal weight" rating on the stock in a research report on Thursday, January 30th. UBS Group dropped their target price on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a "neutral" rating on the stock in a research report on Tuesday, January 28th. HC Wainwright reissued a "buy" rating and set a $10.00 target price on shares of Zentalis Pharmaceuticals in a research report on Thursday, March 27th. Finally, Wedbush reaffirmed a "neutral" rating and issued a $4.00 price objective on shares of Zentalis Pharmaceuticals in a report on Friday, March 28th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $8.24.

Zentalis Pharmaceuticals Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.